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Abstract
Graves’ disease (GD) is an autoimmune disease caused by autoantibodies against 
thyroid stimulating hormone receptor (TSH-R), resulting in stimulation of thyroid 
gland and overproduction of thyroid hormones resulting in clinical manifestations. 
It is uncommon in children and is 6 times more prevalent in females. The symptom-
atology, clinical and biochemical severity are a function of age of onset of disease. 
Prepubertal children tend to present with weight loss and bowel frequency, associ-
ated with accelerated growth and bone maturation. Older children are more likely 
to present with the classical symptoms of thyrotoxicosis like palpitations, tremors 
and heat intolerance. Prepubertal children tend to have a more severe disease, 
longer duration of complaints and higher thyroid hormone levels at presentation 
than the pubertal and postpubertal children. The non-specificity of some of the 
symptoms in pediatric age group can lead to children being initially seen by other 
specialities before being referred to endocrinology. Management issues are decided 
based on patient’s priorities and shared decision making between patient and 
treating physician. Radioactive Iodine Ablation is preferred when there is relatively 
higher value placed on Definitive control of hyperthyroidism, Avoidance of sur-
gery, and potential side effects of ATDs. Similarly Antithyroid drugs are chosen 
when a relatively higher value is placed on possibility of remission and avoidance of 
lifelong thyroid hormone treatment, Avoidance of surgery, Avoidance of exposure 
to radioactivity. Surgery is preferred when access to a high-volume thyroid surgeon 
is available and a relatively higher value is on prompt and definitive control of 
hyperthyroidism, avoidance of exposure to radioactivity and avoidance of potential 
side effects of ATDs. Continental differences with regards to management do exist; 
radio-iodine ablation being preferred in North America while Anti-thyroid drug 
treatment remains the initial standard care in Europe.
Keywords: Graves, hyperthyroidism, radioactive iodine, antithyroid, thyrotoxicosis, 
children
1. Introduction
Graves’ disease (GD) is an autoimmune disease caused by autoantibodies against 
thyroid stimulating hormone receptor (TSH-R), resulting in stimulation of thyroid 
gland and overproduction of thyroid hormones resulting in clinical manifestations. 
GD is a relatively uncommon entity in pediatric age group, in contrast to adults, 
where prevalence ranges from 0.5–1%. Pediatric GD in the age group 0–15 years 
comprises of only 5–6% of the total number of Graves’ thyrotoxic patients. It usually 
occurs in the context of a family history of autoimmune thyroid disease or in asso-
ciation with other autoimmune diseases like type 1 diabetes, Hashimoto’s thyroiditis, 
rheumatoid arthritis or adrenal insufficiency. It is also found in association with 
Graves’ Disease
2
genetic syndromes like Down’s syndrome and Turner’s syndrome. However, GD is 
the most common cause of thyrotoxicosis in children, accounting for atleast 95% 
cases of hyperthyroidism and 10–15% of all childhood thyroid disorders [1]. Other 
rare causes of juvenile thyrotoxicosis include toxic adenoma (TA), toxic multinodu-
lar goitre (TMNG), McCune Albright syndrome (MAS), Hashimoto’s thyroiditis and 
iatrogenic causes. In children, GD can occur at any age, but is most often diagnosed 
in adolescent age group, occurring more frequently in females than in males [2, 3].
The eye changes accompanying GD are termed thyroid-associated ophthal-
mopathy (TAO) or Graves’ ophthalmopathy (GO). The symptoms of GO can run 
an independent course from the clinical course of thyrotoxicosis and often require 
specific treatment. Clinical characteristics of GO are often milder in children than 
in adults, nevertheless adversely affecting quality of life.
2. Epidemiology
Very few epidemiological studies are available to document the incidence of 
pediatric Graves disease in different populations, mostly involving Northern 
Europe and Hongkong. These have resulted in widely variable incidence rates, rang-
ing from 0.79 to 6.5/100000 patient-years [4–9]. Iodine intake in populations could 
be one of the factors for differences observed in different populations, with higher 
incidence rates being observed in populations with higher iodine intake, particu-
larly in studies from Hong-Kong compared to Caucasian children [7, 8].
GD, in concordance with other autoimmune disorders, is more common in 
females, particularly after 4 years of age. Female to male ratio has varied from 2.37–9.7 
in various studies, depending on the age groups included [9]. The female preponder-
ance becomes particularly marked in adolescent years, merging into the adult trends.
In one of the earliest nation-wide comprehensive studies, the incidence ratio 
of thyrotoxicosis was 0.79/100 000 person-years in Danish children under the age 
of 15 years between 1982 and 1988. The incidence was very low in age < 4 years, 
gradually increasing in both genders to peak incidence at 10–14 years of age. As with 
other autoimmune disorders, there was a female preponderance of 6.7: 1, but this 
difference was virtually non-existent in age group 0–4 years. The gender disparity 
widened gradually after early childhood to reach the maximum in the 10–14 year 
age group. Diffuse toxic goitre accounted for 96% of the cases, toxic adenoma and 
toxic multi-nodular goitre (MNG) were rare entities [4].
However, a more recent study in the Danish population spanning between 1998 
and 2012 revealed a higher incidence rate of 1.58/100000 person-years [6], GD 
accounting for 86.8% of the cases. This increasing trend was consistent with rising 
incidences of other autoimmune disorders like type 1 diabetes and celiac disease. The 
authors postulated that environmental factors, including hygiene hypothesis, could 
play a key role in explaining the increasing trends in autoimmune disorders [6].
Similar trends of rising incidence rates have also been documented in studies 
from Hong-Kong as well. This could not be explained by the slight advancement in 
pubertal age or increasing disease awareness. The trends were primarily ascribed 
to the increasing iodine intake in the population, reflected by high urinary iodine 
concentration in the population [7, 8].
Similar to GD, GO is rare in pediatric age group. One of the earliest data about 
the incidence of pediatric GO came from the Olmsted County cohort study from 
Minnesota, USA. The study identified 120 incident cases of GO from 1976 to 1990. 
Peak incidence of GO had a bimodal distribution in the age groups 40–49 year and 
60–69 years in both females and males, with a 5 year later presentation in males. 
The overall age-adjusted incidence rates per 100000 population were 16 and 2.9 
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cases in females and males respectively. On the other hand, GO was much less fre-
quent in the pediatric age group. Incidence rates per 100000 population per year in 
the age groups 5–9, 10–14, and 15–19 years were 3.5, 1.8 and 3.3 and 0, 1.7 and 0, for 
females and males respectively. Only 6 out of the 120 incident cases of GO observed 
in this cohort study were in patients below the age of 20 years [10]. The prevalence 
of GO in different countries has also been seen to be directly related to the preva-
lence of smoking in teenage population in the respective countries, emphasising the 
importance of smoking as risk factor for development of GO [11].
3. Pathogenesis
GD is a classical autoimmune disorder, characterised by a complex interplay of 
genetic susceptibility and environmental factors. GD had long been recognized 
as having a genetic background in view of clustering of cases in families. Family 
H/O autoimmune thyroid disease (AITD) is apparent in nearly half of the affected 
patients. AITD also tends to occur in more than a third of siblings and thyroid auto-
antibodies occur in over half of asymptomatic children of affected patients. This 
was further confirmed by twin studies where concordance of AITD in monozygotic 
twins was 30–40%, as compared to less than 5% concordance in dizygotic twins. 
It has also been proposed that genetic anticipation may occur in successive genera-
tions leading to younger ages at onset of disease [12, 13].
The genetic predisposition to GD is polygenic in origin, with each individual 
gene conferring a modest increase in risk. The most commonly implicated genes are 
located in the HLA region in the short arm of chromosome 6, the odds ratio (OR) 
for GD ranging from 2 to 4. HLA DRB1*03 and DQA1*05 in Caucasian patients, and 
HLA DPB1*05:01 allele in Han Chinese populations have been found to confer 2–3 
times increased risk of GD. Similarly HLA class I alleles C*07 and B*08 have also 
been implicated as risk factors, and DRB1*07, DRB1*12:02, DQB1*03:02, B*44, C*03, 
C*16 have been observed to have a protective effect in various populations.
Some of the other genes which confer a modest increase in risk of GD (OR 
ranging from 1.1–2) are Protein Tyrosine Phosphatase-22 (PTPN22), Cluster of 
Differentiation 40 (CD40), Cytotoxic T-lymphocyte-associated factor 4 (CTLA4), 
TSH-R, Thyroglobulin (Tg), FC-Receptor Like-3 (FCRL3), Secretoglobin 3A2 
(SCGB3A2), Interleukin-2 receptor alpha (IL2RA) etc. Possible mechanisms 
postulated are variation in binding of self-antigens, defective regulation of thymic 
selection of autoreactive clones, regulation of T cell responses and effect of HLA 
class I molecules on natural killer cells.
Some studies have also observed genotype phenotype correlation. For example, 
several genes like interferon γ (IFN 𝛾, TNF, IL-1A, IL-23R, IL-5, CTLA4, PTPN-12, 
ICAM-1 have been associated with development of Graves ophthalmopathy (GO). 
Similarly several candidate genes have been associated with clinical course of GD, 
including age of onset (HLA, ICAM-1, PTPN22, NFKB1, CD40), severity and 
remission/relapse rates of GD (CTLA4, CXCL10) [14].
With the concordance rate in monozygotic twins being clearly less than 100%, 
it highlights the importance of environmental factors for predisposing an indi-
vidual for developing GD. Analysis of Danish twin studies in GD attributed 79% 
of liability to develop GD on genetic factors, whereas 21% could be explained by 
environmental factors not shared by the twins [15].
Stressful life events and post-partum periods can result in a dysregulated 
immune response, predisposing to autoimmunity. Smoking, radiation, excess 
iodine intake, dietary selenium deficiency, drugs like amiodarone, interferons, 
alemtuzumab have been associated with development of AITD. Recent evidence has 
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brought into light the role of Endocrine disrupting chemicals (EDCs), which are 
environmental toxicants that interfere with thyroid hormone production, metabo-
lism and action. Most widely studied EDCs are polychlorinated biphenyls (PCBs), 
which have thyroid-disrupting effects and can have intrinsic thyroid hormone ago-
nist action. Others chemicals like bisphenol A, phthalates, perflourinated chemicals 
and brominated flame retardants have also been shown to have thyroid-disrupting 
effects, predisposing to AITD [16, 17].
The thyroid gland typically demonstrates a non-homogenous lymphocytic 
infiltration and absence of follicular destruction. T-lymphocytes can cause local 
inflammation and cytokine release resulting in dysregulation of B- cells and 
production of autoantibodies. These TSH-R auto antibodies (TRAb) can bind to 
the TSH-R on thyroid follicular cells. These are of the IgG1 subclass and can have 
different functional implications of stimulation, blockade or neutral effects on the 
TSH-R. Thyroid stimulating antibodies (TSIs) act via G proteins like Gs and Gq 
to cause increased thyroid hormone production, secretion and modulation of cell 
proliferation respectively [2, 18].
Graves ophthalmopathy is a distinct pathological process that may precede or 
follow the hyperthyroid phase. Orbital fibroblasts are the target cells in the pathol-
ogy. Plausible explanation for this cellular origin include antigen sharing with the 
TSH-R, enhanced expression of Thy-1 (CD90) and IGF-1 receptor, exaggerated 
inflammatory response to cytokines and hyaluronan synthesis. Environmental 
factors like smoking and radioiodine therapy play a major role in development of 
ophthalmopathy [19].
4. Clinical features
GD can present at any age, with peak prevalence occurring in adolescent years. 
Around 10% of cases can present in very young children less than 5 years of age. 
GD is clinically characterized by the triad of thyrotoxicosis, ophthalmopathy and 
dermopathy. GD in children often presents with classical symptoms and signs of 
thyrotoxicosis like in adults.
The frequency of the symptomatology, however, is variable across literature. 
Major presenting symptoms symptoms include goitre (19–99%), excessive sweating 
and heat intolerance (28–53%), fatigue or weakness (10–54%), irritability, ner-
vousness or restlessness (17–47%), tremors (17–58%), ocular symptoms, ophthal-
mopathy or exophthalmos (10–43%), weight loss or no weight gain (28–63%), 
tachycardia (34–45%). Decreased academic performance can be seen in 1–24% 
of patients, whereas decreased athletic performance can be seen in upto 15% of 
patients. Other common complaints included behavioural changes (50%), headache 
(1–22%), increased bowel frequency (11–16%) and slight fever (10.5%) [5, 20–22]. 
Children can also present with ocular complaints like pain, foreign body sensation 
and grittiness, tearing, redness, photosensitivity, and rarely diplopia [23].
Children, like adults, can have low bone mass for age and increased fracture risk 
in the presence of untreated thyrotoxicosis, but this is often reversible once euthy-
roidism is restored for 2 years with treatment. Thyrotoxicosis may rarely be associ-
ated with choreiform movements in childhood and adolescence. This may manifest 
as involuntary, coordinated, rapid spastic movements like flexion and extension of 
fingers, raising and lowering of shoulders and grimacing. Thyrotoxicosis can also 
result in proximal muscle weakness and wasting syndrome, termed the thyrotoxic 
myopathy, which can mimic limb girdle muscular dystrophy. Importantly, these 
symptoms can even precede the more typical thyrotoxic symptoms. Another type of 
muscular weakness associated with thyrotoxicosis is thyrotoxic periodic paralysis, 
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characterized by recurrent transient episodes of muscular weakness, usually pre-
cipitated by a stressor event like exposure to cold, high carbohydrate meal, infec-
tions and stress. This phenomenon has been more commonly described in Asian 
populations in middle aged males. It is rare in pediatric age groups, and is virtually 
not reported in very young populations [24].
The symptomatology, clinical and biochemical severity are also a function of 
age of onset of disease. Prepubertal children tend to have a more severe disease, 
longer duration of complaints and higher thyroid hormone levels at presentation 
than the pubertal and postpubertal children. Prepubertal children tend to present 
with weight loss and bowel frequency, associated with accelerated growth and bone 
maturation. Older children are more likely to present with the classical symptoms of 
thyrotoxicosis like palpitations, tremors and heat intolerance [25].
The risk of developing GO in pediatric GD appears to be to be similar to or slightly 
higher than the risk in adult patients with GD. Female preponderance (87%) is also 
similar to that observed in adult patients (83%). However, pediatric GO tends to be 
less severe and debilitating as compared to adult manifestations. Soft tissue involve-
ment, lid lag, proptosis and punctate corneal epithelial erosions are more commonly 
seen with pediatric GO, whereas the more severe manifestations like restricted ocular 
motility, severe strabismus and optic nerve affection are virtually never seen in 
pediatric GO. This has been attributed to the lower prevalence of smoking in children 
as compared to adults. Manifestations of GO tended to become similar to adults as 
adolescence approached in pediatric patients with GO in another study, likely due to 
increased prevalence of smoking in adolescent ages. Hence active or passive smoking 
seems to increase the risk and severity of GO in children as well as adults [11, 26, 27].
The non-specificity of some of the symptoms in pediatric age group can lead 
to children being initially seen by psychologists, gastroenterologists, neurologists, 
cardiologists and ophthalmologists, before being referred to endocrinology.
Examination may reveal tachycardia, increased blood pressure for age and raised 
pulse pressure. Skin may be warm and moist, thinning of hair, onycholysis and 
softening of nails can be present.Vitiligo and alopecia areata can be seen in patients 
with associated autoimmune disorders. Precordial pulsations may be prominent, 
accompanied by a apical systolic regurgitant murmur due to functional mitral 
insufficiency secondary to papillary muscle dysfunction. Tremors may be present, 
along with hyperactive deep tendon reflexes. Musculoskeletal examination may 
reveal proximal muscle weakness and wasting.
On local examination, size of the gland can be variable, with a large propor-
tion of patients having none to small or moderate sized goitre, which may escape 
patient’s and family’s attention [28]. The thyroid gland is usually symmetrically 
enlarged, non-tender, smooth and having firm consistency, and may be associ-
ated with a palpable thrill and a thyroid bruit in upto one fourth of patients due 
to increased vascularity. A large goitre can cause tracheal compression and other 
compressive symptoms.
Lid retraction, especially of the upper eyelid, and a staring appearance may be 
evident in upto one-third of the cases. Lid retraction is a sign of adrenergic overac-
tivity, and is not considered a sign of GO per se. Other common signs in pediatric 
GO are lagophthalmos or von Graefe’s sign (9–74%), proptosis (4–91%), signs of 
soft tissue involvement (19–26%), including conjunctival injection (8–49%), che-
mosis (1–23%) and lid edema in around 10% of the patients. Corneal involvement 
can occur in the form of corneal punctate staining (12–34%), exposure keratitis and 
superior limbic keratitis. Extraocular muscle motility defects has been described in 
relatively fewer number of patients (2–11%), except in a study by Eha et al., where 
it was observed in 36% of the patients [23] (Table 1). Similarly, dysthyroid optic 
neuropathy (DON) can be seen very rarely in pediatric age groups.
Graves’ Disease
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Some of the key differences in the presentation of pediatric GD vis-à-vis adult 
GD are as follows:
• Weight loss is less common in children. Increased appetite with/without 
weight loss, or absence of weight gain during pubertal years can be an indi-
cator of thyrotoxicosis. Growth charts can be pivotal in identifying trends 
for early detection. BMI SD scores have been reported to be particularly 
lower in younger children as compared to older children in few studies.
• Early symptoms like behavioural changes, emotional lability, fatigue, 
nervousness, palpitations, sleep disturbances with insomnia are particularly 
subtle and difficult to identify.
• Difficulty in concentrating, restlessness, hyperactivity, impaired scholastic 
performance can be the presenting complaints, especially in younger children. 
These can be commonly mistaken to be Attention deficit hyperactivity disorder 
(ADHD), leading to a delay in diagnosis and treatment.
• Untreated thyrotoxicosis can lead to increases in height velocity and advance-
ment of skeletal age, which can be apparent as an increased height SDS in 
Differences Pediatric Graves Adult Graves
Symptoms Classic symptoms less common






Pretibial Myxedema Rare 5%
(15% in Graves disease with 
ophthalmopathy)
Thyroid storm Rare 1–2%
Atrial fibrillation Rare 10–15%
(25% in age > 60 years)




(Lower rates in prepubertal children 
~17%)
40–60%
Surgery Higher complication rates
Requires experienced high-volume 
thyroid surgeon
Relatively safe and easy surgery
Cosmesis Greater concern Lesser concern
RAIA Increased sensitivity to radiation
Increased susceptibility to 




Differences in Pediatric vs. Adult Graves Disease.
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growth charts. Increase in height SDS is seen more commonly in prepubertal 
children than pubertal and post-pubertal children. This may be explained by 
the fact that prepubertal bone maturation is driven by growth hormone (GH) 
and thyroid hormones, whereas pubertal bone growth is driven primarily by 
estradiol. Another plausible reason could be the delay in diagnosis in younger 
children. The effect on final height, however is variable across literature, where 
some studies show achievement of a normal height within target range, some 
showing increased final height [25, 29]
• Ophthalmic abnormalities are less severe. Soft tissue involvement, lagophthalmos, 
proptosis and punctate corneal erosions more common, extraocular muscle 
restriction and optic neuropathy are rare
• Pretibial myxedema is rare (0.9%)
• Atrial fibrillation is rare
• Thyroid storm is rare in children
Pediatric GD can commonly be associated with other conditions as follows 
[2, 30].
5. Differential diagnosis
GD is the most common cause of thyrotoxicosis in children. However, it has 
to be clinically differentiated from other causes of thyrotoxicosis in childhood. 
These include hyperthyroid disorders, associated with increased secretion of the 
thyroid hormones from the thyroid gland, or cases of thyroiditis, where symp-
toms occur due to thyroid follicular disruption leading to release of preformed 
causes. Some of the common differential diagnostic causes have been summarized 
in Tables 2-4.
Consumption of biotin as a part of management of metabolic or dermatological 
diseases can lead to surreptitious laboratory results of elevated thyroid hormones, 
suppressed TSH and positive thyroid receptor autoantibodies with immunoas-
says utilizing the streptavidin-biotin platforms. Hence, laboratory results must 









• Type 1 diabetes
• Primary adrenal insufficiency
• Vitiligo
• Systemic lupus erythematosus 
(SLE)





Common associations of pediatric GD.
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Acute suppurative thyroiditis • Bacterial infection: Haemophilus influenza, Group A streptococci
• Painful thyroid, fever, fistula can be present
• Transient thyrotoxicosis
• Associated with elevated ESR and WBC count, decreased uptake 
on nuclear scan (Tc-99 m or radioiodine)
Subacute granulomatous 
thyroiditis/ de Quervain disease
• Viral infection
• Fever, painful thyroid, symptoms less severe than bacterial 
thyroiditis
Hashimoto’s thyroiditis • 5–10% of children can present with “Hashitoxicosis”
• Transient thyrotoxicosis
• Low or absent uptake in thyroid on nuclear scans
Thyroid injury • H/O significant neck trauma or exposure to radiation
Thyrotoxicosis factitia • Exogenous ingestion of thyroid hormones, particularly in the 
setting of adolescents trying to lose weight
• Low or absent thyroid uptake in nuclear scans
• Low serum thyroglobulin is diagnostic
Table 4. 




TA • Focal increase in uptake on nuclear scans with suppressed uptake in rest of the 
gland
• Surgical excision preferred therapy
TMNG • Multiple foci of increased uptake with suppressed uptake in remainder of the 
gland on nuclear scan
• Surgery preferred modality
Germline activating 
mutations of TSH-R
• Familial or denovo forms
• Can lead to simple or multinodular goitre
McCune Albright 
syndrome
• One-third can develop hyperthyroidism




• Elevated T4 with an inappropriately normal TSH
• High serum alpha subunit concentration and alpha subunit to TSH ratio, little 
to no response to thyrotropin releasing hormone (TRH)
Resistance to thyroid 
hormone
• Autosomal dominant
• Elevated T4 with a normal or elevated TSH
• Generally euthyroid, clinical manifestations depend on the site of the defect in 
thyroid hormone receptor
Table 3. 
Differential diagnosis of GD: Hyperthyroid disorders.
9




6.1.1 Thyroid function tests
All patients with suspected thyrotoxicosis should undergo detailed thyroid func-
tion tests, including TSH, free thyroxine (FT4) and preferably total triiodothyro-
nine (T3). Measurement of total T3 is preferred over free T3 (FT3) as the FT3 assays 
are less robust and less validated as compared to the FT4 assays. Measurement of 
free hormones makes the assay reports more reliable in the presence of conditions 
affecting the concentrations of thyroid binding globulin (TBG) like liver disease, 
nephrotic syndrome. Serum TSH is more sensitive the changes in thyroid hormone 
levels due to the log-linear relationship of TSH with the free thyroid hormone levels.
Assays have been constantly evolving from the older manual radioimmunoas-
says (RIA) to the modern day fully automated chemiluminescent immunoassay 
(CLIA) and electrochemiluminescent immunoassay (ECLIA) platforms. Results 
have to interpreted in the light of age and assay-specific reference ranges. Lack of 
consistency between biochemical reports and clinical presentation should alert the 
physician to consider assay interferences like presence of heterophile antibodies and 
excess biotin consumption.
Thyroid function tests typically reveal elevated free thyroxine (FT4) and T3 
with a suppressed TSH in overt thyrotoxicosis. Patients with milder thyrotoxicosis 
may exhibit only elevated T3 values and suppressed TSH with normal T4 values, a 
state known as T3 toxicosis, a common presentation in pediatric age groups. Higher 
T3 values have been noted in prepubertal children as compared to post-pubertal 
children, and have been observed to be a negative predictor of the likelihood of 
remission in pediatric GD [25, 32].
6.1.2 Markers of thyroid autoimmunity
TRAbs are specific for GD, and are found in majority of the patients at diagno-
sis, with a reported prevalence of >70% in pediatric GD in some studies [33, 34]. 
TRAb levels can be higher in younger patients <5 years of age and in clinically severe 
disease [2].
Traditionally, TRAb concentrations were measured using either bioassays or recep-
tor assays. Estimation of TRAb levels by bioassays was based on the ability of TRAbs 
to increase cyclic adenosine monophosphate (cAMP) production either directly from 
thyroid follicular cells in vitro, or indirectly via TSH-R transfected Chinese hamster 
ovary (CHO) cells. These also enabled detection of functional subtypes of TRAbs, 
including inhibitory TRAb antibodies. Receptor assays, on the other hand, provide 
an estimate of TRAb levels by measuring the ability of TRAb to inhibit the binding of 
labelled TSH to thyroid membranes, and provided enhanced sensitivity [1].
TRAb assays subsequently evolved with the advancements in immunoassays 
techniques. The “liquid phase” first generation immunoassays were competitive 
immunoassays based on inhibition of binding of radionuclide or enzyme labelled 
TSH. These provided excellent specificity of 97.5–100%, but suffered from a 
suboptimal sensitivity ranging from 52 to 94%. Subsequently, 2nd generation “solid 
phase” immunoassays utilized monoclonal antibodies and human or porcine TSH-R 
immobilized on a solid surface, improving the sensitivity to 87–100%. The 3rd 
generation immunoassays utilized a stimulating biotinylated monoclonal antibody 
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(M22) to bind to immobilized TSH-R. In recent years, fully automated platforms 
have been developed using the ECLIA and fluoroenzymatic immunoassay prin-
ciples, with excellent sensitivity of 95–100% and specificity of 97–100% [35].
GD may also be associated with other anti-thyroid antibodies like thyroid 
peroxidase (TPO) autoantibodies, anti-thyroglobulin antibodies, as well as other 




Thyroid scans utilize a gamma camera to provide a planar image, which 
provides anatomical information in addition to the functional status, whereas 
uptake scans are used to measure the % radioiodine uptake (RAIU), typically 
measured by placing a non-imaging gamma scintillation probe detector over the 
neck. Most commonly used radiopharmaceuticals for nuclear thyroid imaging 
are iodine-123 (I-123) and 99 m-technetium (Tc99m-pertechnetate). Drugs 
which can potentially interfere the tracer uptake like thionamides and sources of 
excess iodine have to be stopped atleast 3–7 days and 2–4 weeks prior to the study 
respectively. The doses for diagnostic imaging should be weight-based rather 
than fixed doses especially in children. The scintigraphic images and uptake 
studies are typically performed around 4 hours after I-123 intake, or 20 minutes 
after the iv injection of Tc-99 m pertechnetate. While technetium scans result in 
a low radiation exposure, they result in a high background noise and a low range 
of normal uptake in the thyroid gland [36].
GD is characterized by a homogenous increase in tracer uptake in the thyroid 
scans and an increased %RAIU on uptake studies. These studies are not done rou-
tinely for diagnosis in pediatric GD. Their primary role is in differential diagnosis 
of thyrotoxicosis in cases with inconclusive clinical and biochemical findings, and 
in assessing the radioiodine uptake in order to calculate the dose of therapeutic 
I-131 when radioiodine ablation is planned as therapy. However, germline TSH-R 
activating mutations can also give rise to a diffuse and homogenously increased 
uptake in the thyroid gland. On the other hand, McCune Albright syndrome, TA 
and TMNG are typically associated with focal increases in uptake with suppressed 
uptake in the remainder of the gland, whereas autoimmune thyroiditis, iodine 
excess and thyrotoxicosis factitia are associated with decreased to absent uptake 
in the thyroid gland [22, 37].
6.2.2 Thyroid ultrasonography
A thyroid ultrasound and doppler study provides a safe and non-invasive modal-
ity for differential diagnosis of thyrotoxicosis. Thyroid gland is classically diffusely 
enlarged in GD, and may display normal echogenicity or hypoechogenicity like 
in thyroiditis. GD is characterized by a diffuse increase in parenchymal vascu-
larization, often referred to as a “thyroid inferno”. Autoimmune thyroiditis may 
be associated with a lesser degree of increase in parenchymal vascularity as well. 
Quantitative measurements of the thyroidal blood flow can also be vital in diagnos-
ing GD, with superior and inferior thyroidal artery’s mean peak systolic velocities of 
more than 45–50 cm/second suggestive of a diagnosis of GD, providing a sensitivity 
and specificity of 81–83% and 92–96% respectively.
Ultrasound should also be performed in the case of thyroid asymmetry or a 
palpable nodule [2, 18, 38–40].
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7. Management
The three cornerstones of management of pediatric GD are antithyroid drugs 
(ATDs), radioiodine (RAI) therapy and surgical management. Age of the patient, 
likelihood of remission, availability of expertise and facilities, patient preferences 
determine the choice of modality. The choice of initial therapy also depends on 
the prevailing practices in different geographic regions of the world. For instance, 
antithyroid drug therapy remains overwhelmingly the most popular choice in 
Japan, with >90% of children with newly diagnosed GD being instituted on ATDs, 
whereas the proportion is >80% in Europe, Asia, Oceania and South America. 
RAI therapy is more commonly used in the United States of America, with >70% 
of newly diagnosed pediatric GD patients being treated with I-131 previously. 
However, the use has been declining, with current estimates of 40% of patients 
being instituted on ATDs [22].
7.1 Medical management
Antithyroid medications still remain the modality of choice in most pediatric 
patients with GD, despite lower remission rates as compared to adults. Methimazole 
(MMI) or carbimazole (CBZ) are the drugs of choice, with the former used com-
monly in the United States and Japan, and the latter being used in Europe.
All the drugs act by inhibition of the critical enzyme thyroid peroxidase, effec-
tively inhibiting the organification of iodine by inhibiting its binding to the tyrosyl 
residues on thyroglobulin. They also inhibit thyroglobulin synthesis, coupling of 
iodotyrosine residues, and secretion of thyroid hormones. PTU additionally inhibits 
type 1 deiodinase enzyme, decreasing the conversion of T4 to the peripherally 
active T3. Carbimazole is a prodrug and it get converted to methimazole completely 
after hepatic metabolism. 10 mg CBZ is equivalent to 7.5 mg MMI and 100 mg PTU. 
Besides the differences in potencies, the drugs differ in their pharmacokinetics, 
with MMI having a half-life of 6–8 hours, whereas PTU has a much shorter half-life 
of 30 minutes, necessitating 3 times a day dosing [22].
7.1.1 Dosing considerations
The starting dose of MMI is typically 0.2–0.5 mg/kg/day, ranging from 0.1-1 mg/
kg/day. French guidelines suggest a dose of 0.4 mg/kg/day in moderate thyro-
toxicosis (FT4 < 50 pmol/L), and doses of 0.8 mg/kg/day in severe thyrotoxicosis 
(FT > 70 pmol/L). As MMI is usually available in the form of 5 or 10 mg tablets, ATA 
guidelines also put forth a simplified guideline to ease administration, suggesting 
doses of 1.25 mg/day, 2.5–5 mg/day, 5–10 mg/day and 10–20 mg/day in the age groups 
of infancy, 1–5 years, 5–10 years and 10–18 years respectively, with dose escalation 
of 50–100% above the suggested doses in cases of severe hyperthyroidism. The doses 
are typically administered in a single dose or divided into two or three doses a day in 
the initial stages. Single dose therapy may result in better patient compliance.
PTU may be considered in doses of 2–7.5 mg/kg/day in three divided doses. But 
it is strictly avoided in pediatric patients due to concerns of severe hepatotoxicity, 
except in cases of thyroid storm and patients with adverse reactions to MMI requir-
ing short-term control of thyrotoxicosis prior to definitive therapy. French guide-
lines contraindicate PTU use in children, and Japanese guidelines advocate caution 
with PTU use [22, 31, 36].
Symptoms of sympathetic overactivity including tremors, tachycardia, muscle 
weakness, neuropsychological disturbances are treated with beta blockers, pro-
pranolol at 1–2 mg/kg/day in 2–3 divided doses, or atenolol at 0.5–1.2 mg/kg/day as 
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a once daily dose. Selective beta blockers like atenolol and metoprolol are preferred 
in children with reactive airway disease [22, 31, 36].
7.1.2 Adverse effects
Most adverse reactions to antithyroid drugs emerge within 3 months of initiat-
ing treatment. PTU was widely used for medical management of pediatric GD until 
it fell out of favour in early 2000s, due to multiple reports of serious hepatotoxicity. 
PTU is associated with idiosyncratic hepatocellular necrosis, leading to hepatic 
dysfunction ranging from reversible injury to acute liver failure requiring trans-
plantation, and rarely leading to death. PTU was the third most common cause of 
drug-induced liver failure, accounting for approximately 10% of drug-related liver 
transplantations in the United States [41].
The risk of hepatotoxicity is considerably higher in children than in adults, with 
children accounting for almost half of the patients in case reports of PTU-induced 
liver failure. Rivkees et al. estimated that the risk of reversible liver injury in chil-
dren taking PTU was atleast 1 in 200, and the risk of liver failure requiring trans-
plantation was atleast 1 in 2000–4000. It was also noted that PTU-induced liver 
failure was rapidly progressive and with low chances of reversibility, and there were 
no meaningful biochemical markers to predict the risk of hepatotoxicity [42]. FDA 
issued a boxed warning for PTU use in 2010, noting that 22 adult and 10 pediatric 
cases of serious liver injury were associated with PTU use, and limited its use to 
patients intolerant to other modalities and in first trimester of pregnancy [43].
MMI can also be associated with hepatotoxicity, although it is typically milder 
and of the cholestatic pattern. No cases of liver failure or transplantation have been 
reported in association with MMI use in children, in contrast to adults in whom 
hepatocellular toxicity has been described.
PTU is also associated with a 40 times higher risk of antineutrophil cytoplasmic 
antibody (ANCA) vasculitis than with MMI use. The positivity rate of ANCA in 
pediatric users is higher, approximately 64%, approximately 20% of whom can 
develop vasculitis. The antibodies tend to develop at or after 1 year of treatment. 
Usually asymptomatic, it can occasionally manifest as polyarthritis, dermatologic 
involvement in the form of purpuric skin lesions, pulmonary and renal involvement. 
There exist few case reports of renal failure in children due to vasculitis. Majority 
of the cases resolve with discontinuation of the offending medication, but severe 
involvement may require glucocorticoid and other immunosuppressive therapy.
MMI is more commonly associated with minor adverse events in upto 25% of 
the children being treated with MMI, most commonly involving mucocutaneous 
adverse events like urticaria, rash, oral ulcers and arthralgias, myalgias. The risk of 
agranulocytosis appears to be similar for MMI and PTU, affecting 0.3% of treated 
adults, with possibly lower prevalence in children. The risk appears to be dose-
dependent with MMI use, with most of the cases occurring with daily MMI doses 
exceeding 20 mg/day.
Minor allergic reactions are usually managed with antihistamines, while continuing 
the drug under watchful guidance. On the other hand, occurrence of serious adverse 
reactions warrant drug discontinuation and consideration of alternative therapies. 
PTU and MMI exhibit significant cross-reactivity, hence use of either drugs should be 
avoided with the occurrence of a serious adverse reaction to the other drug [22, 31, 36].
7.1.3 Monitoring and dose titration
Patients should be monitored clinically for symptoms and signs of thyrotoxi-
cosis. Weight and height should be checked periodically during clinic visits and 
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charted in appropriate growth charts. Parents should also be counselled about 
possible weight gain in the first few months of therapy, which can persist.
ATA guidelines suggest a complete hemogram and liver function testing prior to 
initiating ATDs. Routine monitoring of WBC counts and liver function tests is not 
advocated due to sudden onset of agranulocytosis and rapidly progressive nature 
of PTU-related hepatotoxicity. WBC counts should be ordered in the presence of 
febrile illnesses or pharyngitis. Similarly, liver functions should be obtained when 
patients develop symptoms of hepatotoxicity like jaundice, pruritus, anorexia, 
light-coloured stools or dark urine, drug should be discontinued if transaminases 
are elevated upto 2–3 times the upper limit of normal. Subsequently, liver function 
tests should be monitored till normalization. Japanese guidelines also advocate 
annual urinalysis and MPO-ANCA measurement for early detection of ANCA-
associated vasculitis in children on PTU [22, 36].
Thyroid function tests should first be obtained after 2–6 weeks of initiation of 
therapy, every 4–6 weeks till dose is stabilized and every 3 months thereafter. MMI 
dose can be reduced by 50% once thyroid hormones normalize. The usual mainte-
nance doses range from 5 mg every alternate day to 10 mg a day [22, 36].
Alternatively, “block and replace” strategy has been used, where replacement 
levothyroxine is added so that ATDs can be continued at higher doses. A 2010 
metanalysis by Abraham et al. showed that block and replace regimens had similar 
efficacy to titration regimens, but had higher risk of treatment withdrawal due to 
adverse effects [44]. This is especially true for MMI as most adverse effects of MMI 
are dose-related. However, some authors attributed these findings to the unconven-
tionally higher doses of MMI in the studies using block-and-replace regimens in 
the meta-analysis, and hence maintain that block-and-replace can be a worthwhile 
strategy, especially in patients who are sensitive to minor increases in doses of MMI 
and become hypothyroid [36, 45].
7.1.4 Duration of therapy
Multiple prognostic factors determine the response to antithyroid drugs. It 
is usually assessed by remission rates, defined as the proportion of patients who 
remain euthyroid 1 year after cessation of ATD. Remission rates in children after 
1–2 years of ATD therapy are typically 20–30%, lower than in adults.
In contrast to older studies which suggested a 25% chance of remission for every 
2 years of continued treatment, longer duration of therapy has not translated into 
significant improvements in remission rates in more recent studies. For example, 
treatment beyond 2 years has been seen to associated with remission rates of 
23–37% after 4 years, and only 15% after 4–10 years of therapy. Relapse can occur 
in as many as 36–47% of patients after initial remission. Additionally, longer 
treatment durations carry the risk of non-compliance and drug toxicities. However, 
more recent studies have shown encouraging data on relapse rates. In a retrospective 
study involving 1138 pediatric GD patients by Ohye et al., remission rate was 46% 
after a median duration of 3.8 years of ATD therapy, with no significant predictors 
for remission identified. The cumulative rates of remission increased with duration 
of anti-thyroid medication till 5 years of therapy. Similar findings were seen in the 
prospective study by Leger et al., in which remission rates were 20, 37, 45 and 49% 
after 4, 6, 8 and 10 year of ATD therapy respectively, suggesting a plateau of remis-
sion after 8–10 years of ATD therapy [36, 46, 47].
Evidence for prognostic factors predicting remission and relapse in pediatric 
GD have been mostly derived from many retrospective and few prospective stud-
ies. Older age and pubertal onset of disease, higher BMI, lower levels of thyroid 
hormone levels at presentation, early achievement of euthyroidism within 3 months 
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of institution of ATDs and smaller goitres, have all been associated with early 
remission. Pre-pubertal children also tend to require longer duration of therapy 
to achieve remission vis-à-vis pubertal children [25, 32, 33, 48]. Non-Caucasian 
origin, higher TRAb levels additionally have also been associated with increased 
risk of relapse in treated patients [49]. In a study by Smith et al., TRAb antibodies 
decreased with duration of antithyroid therapy, but normalized only in 18% of 
children even after 24 months of therapy, with no further significant decreases with 
prolonged therapy. This points to a persistence of autoimmunity in pediatric age 
groups in contrast to adults, in whom TRAb levels tend to decline with anti-thyroid 
therapy, and may be used to guide decision-making for stopping anti-thyroid 
medication [50].
ATA guidelines suggest 1–2 years of ATD therapy before considering definitive 
modalities of RAI or surgery, depending on age of the child. Japanese guidelines 
suggest a duration of atleast 18–24 months, extending upto 5–10 years for better 
remission rates. They also suggest utility of TRAb assays in deciding duration of 
therapy.
7.1.5 Other drug therapies
Patients of thyrotoxicosis intolerant to MMI, awaiting surgery can be treated 
with inorganic iodine, either with 3–7 drops thrice a day of saturated solution of 
potassium iodide (SSKI) containing 50 mg iodide per drop, or 3–4 drops a day of 
Lugol’s solution, containing 6.3 mg of iodine per drop, for 10 days prior to surgery. 
Inorganic iodine can also be used in the management of thyroid storm. It acts 
by inhibiting organification of iodine and thyroid hormone release, termed the 
“Wolff-Chaikoff effect”. Caution has to be exercised for potential development of 
escape phenomenon, or exacerbation of thyrotoxicosis after drug withdrawal.
Alternatively, other drugs like lithium carbonate can be used, which acts by 
inhibiting the synthesis and release of thyroid hormones, but needs watchful care 
for any adverse effects. Some of the other medications that have been used are 
perchlorate, cholestyramine, corticosteroids and rituximab [22, 36].
7.2 Radioiodine therapy
The target of I-131 therapy is to achieve hypothyroidism by thyroid ablation with 
a single optimal dose of I-131 rather than euthyroidism. This is particularly relevant 
in pediatric age groups due to sensitivity of the thyroid gland to radiation.
The concerns over increased risk of malignancy with radioiodine were born 
after the Chernobyl incident, where increased risk of thyroid malignancies was 
attributed to low doses of I-131 and other radionuclides, in the presence of a dietary 
iodine deficiency in the population. Importantly, the maximum risk appeared to 
occur in children less than 5–6 years of age, decreasing gradually through 12 years 
of age. However, the highest risk of thyroid malignancy is seen with low levels 
of radiation exposure of about 0.09–30 μCi/g, and not with the higher activities 
administered in treatment of GD.
In a retrospective study by Read et al. involving 36 years follow up of 116 
patients who had received RAI therapy between the ages of 3–19 years, there were 
no cases of thyroid malignancy or leukemia. There was also no increase in con-
genital anomalies in the offspring or rate of spontaneous abortions in the cohort 
[51]. Similarly, no significant increase in risk of non-thyroid malignancies has been 
observed in recipients of I-131 treatment.
Hence, ATA guidelines suggest avoiding RAI therapy in children less than 5 years of 
age, and considering RAI therapy in children between 5 and 10 years of age when the 
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required activity for treatment is <10 mCi, while emphasizing that these restrictions 
are based on theoretical concerns of malignancy [18, 22, 31, 36].
7.2.1 Preparation
ATA guidelines suggest achieving euthyroidism with anti-thyroid drugs and 
beta blockers in patients with total T4 > 20 μg/dl, and free T4 > 5 ng/dl prior to RAI 
therapy. Iodine intake has to be restricted atleast 1 week prior to I-131 therapy. Anti-
thyroid medications are typically stopped 2–3 days prior to administering I-131. 
This is associated with potential risk of worsening thyrotoxicosis and precipitating 
thyroid storm after radioiodine therapy. Alternatively, 20% higher dose can be 
administered while patient is on anti-thyroid medication, minimizing the risk of 
thyroid storm. Either of these approaches have not been well studied in pediatric 
age groups.
ATDs are restarted only 1 week after RAI therapy to optimize the likelihood of 
successful ablation, although this is seldom required in children as thyroid hormone 
levels begin to decrease within one week after RAI treatment [18, 22, 31, 36].
7.2.2 Dosing considerations
The activity to be administered as fixed doses of about 15 mCi or calculated 
using the Quimby-Marinelli formula, or the modified version based on the 
24-hour uptake values on RAIU scan. Estimation of total gland size can be done 
by physical examination or by ultrasound dimensions of the gland, and is particu-
larly challenging in pediatric patients. In general, the total dose of I-131 should be 
atleast 150 μCi/g of thyroid tissue, resulting in hypothyroidism in >95% of cases. 
Increased doses of 200–300 μCi/g may be required in patients with large goitres 
and lower radioiodine uptake. There are no studies available to compare the two 
methods in children.
Radioiodine is retained in the thyroid for several days, and is also excreted in 
body fluids like saliva, tears, sweat, stool and urine. Appropriate local radiation 
safety precautions have to be observed by the patient and family members after RAI 
treatment [18, 22, 31, 36].
7.2.3 Complications
Pain in the gland can develop in the week after I-131 therapy in less than 10% 
of the patients. It can be managed by symptomatic treatment with analgesics for 
1–2 days. There may be temporary exacerbation of thyrotoxicosis, requiring treat-
ment with ATDs, glucocorticoids and iodine preparations. Long-term risks include 
the theoretical risk of secondary malignancies following radiation [36].
7.2.4 Monitoring
Patient has to be clinically monitored for signs and symptoms of hyperthy-
roidism as well as for development of hypothyroidism. Patients can experi-
ence an exacerbation in ophthalmopathy, which may require treatment with 
glucocorticoids.
Hypothyroidism is usually achieved at 1–3 months after an optimal dose of I-131, 
with occasional patients taking upto 6 months to achieve hypothyroidism. Thyroid 
function tests should be obtained 4 weeks after I-131, followed by periodic testing 
at 4–6 weeks till hypothyroidism is achieved, when thyroid hormone replacement 




RAI therapy is an absolute contraindication in children less than 5 years of age as 
per AT and French guidelines. The latter also mention it as a relative contraindica-
tion in pre-pubertal children. Japanese guidelines advocate “careful administration” 
in children younger than 18 years of age on account of risk of thyroid malignancy 
and gonadal injury post radiation.
RAI therapy can be considered in pediatric patients with GO in non-severe 
cases. The NO-SPEC severity classification and clinical activity score (CAS) have 
not been validated in pediatric population. RAI therapy may still be considered in 
the presence of more severe manifestations like corneal involvement, persistent lid 
retraction and chemosis with concomitant oral glucocorticoid therapy, beginning a 
day after RAI, and tapered over 1–3 months [22, 31, 36].
7.3 Surgery
Surgery should be considered in patients with large goitres, presence of com-
pressive symptoms, coexisting differentiated thyroid cancer (DTC), patients 
wishing to achieve faster remission, patients who do not wish to use ATDs or have 
adverse effects or contraindications to use of ATDs. ATA guidelines recommend 
thyroidectomy in children younger than 5 years of age, in whom definitive therapy 
is indicated and have accessibility to surgical expertise.
The major limiting factor for choice of surgery as the modality is the access to a 
high volume thyroid surgeon, defined as performing more than 30 cervical endo-
crine procedures in a year. The surgical complication rates are inversely related to 
the annual number of procedures by the operating surgeon, rather than the training 
or surgical specialty per se. The centre should be capable of handling pediatric anes-
thestic challenges and post-operative intensive care requirements. In the presence of 
availability of expertise and infrastructure, surgery can be offered as equivalent to 
RAI therapy to the parents [18].
7.3.1 Preparation
Patient should be rendered euthyroid with medications prior to surgery 
(thionamides, inorganic iodide and beta blockers). Potassium iodide, containing 
50 mg iodide/drop can be administered as 1–2 drops thrice a day, 7–10 days prior 
to surgery can alleviate thyrotoxicosis as well as decrease vascularity of the gland. 
Dexamethasone can also help in rapid control of thyrotoxicosis [22, 36].
7.3.2 Procedure
Total or a near-total thyroidectomy (with <3 g of residual thyroid tissue) are the 
procedures of choice for management of GD. Partial or subtotal thyroidectomies 
may result in recurrence rates of 10–15%. Intra-operative PTH monitoring can be 
valuable in predicting the occurrence of post-operative hypocalcemia.
7.3.3 Complications
Most common post-operative complications include transient hypoparathy-
roidism and recurrent laryngeal nerve palsy. These complications tend to occur 
at the rate of 10–20%, more frequent than in adults, and are particularly more 
common in younger children. Other severe complications like permanent hypo-
parathyroidism, hematoma, infection, recurrent laryngeal nerve palsy occur less 
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frequently. Significant bleeding occurs more frequently with large goitres, neces-
sitating blood transfusions in children. Caution has to be exercised in handling of 
recurrent laryngeal nerves as they are thinner in children. Growth-related bone 
metabolism may make the patient prone for transient hypoparathyroidism post-
operatively. Post-operative hypocalcemia requiring intravenous calcium correc-
tion occurs more frequently in children. Its risk can be decreased by preoperative 
calcitriol, usually started 3 days before surgery and weaned off over the first 
2 weeks post-operatively.
Surgery offers the advantages of definitive therapy. This has to be weighed 
against the risks associated with an invasive procedure, and the requirement of life-
long thyroxine replacement with appropriate monitoring after surgery [22, 31, 36].
7.4 Choice of modality
Anti-thyroid drugs are usually the first line of management, typically admin-
istered for atleast 1–2 years. Definitive therapy with RAI therapy or surgery 
should be considered if remission is not attained after 1–2 years of ATD therapy. 
Continued medical management with periodic biochemical monitoring is a 
viable option in patients who are not candidates for either of the two definitive 
modalities. They offer the advantages of ease of administration, availability, 
reasonable safety and avoidance of exposure to radioactivity and surgical proce-
dure. These have to be weighed against long duration of therapy and associated 
followup, lower rates of remission, low rates of compliance, higher frequency of 
adverse effects.
Radioiodine therapy in sufficient doses results in achievement of hypothyroid-
ism in majority of patients, and should be considered as the modality of choice 
for definitive therapy in children >10 years of age, and in children 5–10 years of 
age with calculated dose requirements of less than 10 mCi. This has to be balanced 
against the risks of temporary flare, radiation thyroiditis and concerns of malig-
nancy, even if theoretical as per most studies.
Medical management RAI therapy Surgery
• First line of therapy in 
most patients
• Lack of access to defini-
tive therapies
• Good compliance to 
medication and periodic 
followup
• Risk factors for poor response to ATDs:
 ○ Prepubertal
 ○ Severe biochemical thyrotoxicosis 
and elevated TRAb at presentation
 ○ Prolonged time to achieve 
euthyroidism
 ○ Persistently elevated TRAb
 ○ Large goitre
• Adverse effects and poor compliance to 
ATDs
• Contraindications or unwilling for 
surgery
• Relapse after medical and surgical 
management
• Avoidance of surgical scar and risks 
associated with surgery
• Risk factors for poor 
response to ATDs as 
described
• Children younger than 
5 years of age
• Large goitres more than 
twice the normal size for 
age or > 80 g
• Compressive symptoms
• Nodular goitre, suspicion of 
malignancy
• Inability to comply with 
precautions and follow-up 
instructions after RAI 
therapy
• Severe eye disease
• Post-pubertal patients 
considering pregnancy
Table 5. 
Clinical factors influencing choice of modality in pediatric GD.
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Surgery offers immediate and definitive therapy. However, the need for hospi-
talization, associated complications, surgical scarring preclude its use as a first line 
therapy. It can be considered in patients requiring definitive therapy and not being 
suitable candidates for RAI ablation.




Encephalopathy can occur in association with thyroid storm. Initial presentation 
can include mental status changes including behavioural abnormalities, agitation, con-
fusion, anxiety and emotional lability. Patients can also present with seizures, which 
can range from generalized tonic clonic to complex partial to more focal seizures.
8.2 Neonatal GD
Neonatal GD, though rare, can be life-threatening with significant morbidity 
and mortality. Maternal transfer of thyroid-stimulating immunoglobulins (TSIs) 
to the fetus, can occur in 1 in 80 cases of maternal GD. The risk of neonatal GD is 
directly proportional to the magnitude of elevation of TSI levels, typically increased 
at levels 2–4 times the upper limit of normal. The fetal thyroid can respond to TSIs 
resulting in excessive production of thyroid hormones.
This can manifest as fetal thyrotoxicosis, especially in second half of gesta-
tion. The condition should be suspected in the presence of fetal tachycardia (heart 
rate > 160/min after 20 weeks of gestation), goitre on antenatal ultrasound. 
Uncontrolled fetal thyrotoxicosis can result in intrauterine growth retardation 
(IUGR), premature fusion of cranial sutures, advanced skeletal age, accelerated mat-
uration of femoral ossification centre, learning disabilities and mental retardation.
Management consists of adequate control of maternal thyrotoxicosis with 
anti-thyroid drugs. Propylthiouracil (PTU) is often the first choice at the time 
of organogenesis. Methimazole (MMI) is avoided in first trimester due to risk of 
methimazole embryopathy (Odds ratio of 1.66 for developing birth defects). This 
can manifest as aplasia cutis congenita, omphalocele, choanal and esophageal 
atresia and other omphalomesenteric duct anomalies in the newborn [52, 53].
The condition usually resolves by 3–6 months of age, due to clearance of TSIs 
from the infant’s circulation. Infants may meanwhile require medical manage-
ment of thyrotoxicosis. This entails treatment with antithyroid medications (PTU 
5–10 mg/kg/day or MMI 0.5–1 mg/kg/day) and propranolol (1 mg/kg/day). Rapid 
biochemical control may require administration of Lugol’s solution or saturated 
solution of potassium iodide (SSKI) for 7–10 days. Thyroid hormones typically 
normalize after 2 weeks of medical therapy, and may necessitate addition of 
levothyroxine to prevent hypothyroidism. Anti-thyroid medication can usually be 
weaned by 3 months, guided by monitoring of infant’s serum TSI levels.
9. Summary
Graves disease in children is a classic example of children not being small adults. 
There are differences in management and response to treatment in children with 
Graves disease. Nuances exist for the various modalities for children and requires 
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specialist pediatric endocrinology care. Therapeutic options need to be discussed 
with parents before deciding on choice of definitive therapy. Smooth transitioning 




MAS McCune Albright syndrome
TA Toxic adenoma
TMNG Toxic multinodular goitre
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